biOasis Technologies Inc. (South Surrey, BC, Canada) announced that a major step in the application of its p97 test for diagnosis of Alzheimer's disease was achieved by the signing of an agreement with UK-based Fleet Bioprocessing Ltd. (Fleet; Hartley Whitney, UK).

Rob Hutchison, CEO, biOasis commented, ''If earlier diagnosis and improved patient management result in delaying the average onset of the disease by even one-year, society would save in excess of U.S. $12 billion annually. The agreement with Fleet will reduce product development timelines for the biOasis p97 Alzheimer's test and enable faster entry into the $36 billion IVD market."

Fleet Bioprocessing are expert providers of high-quality contract development and manufacturing services. They meet the needs of the diagnostics, pharma, and biotech sectors, offering a range of services from purification and conjugation of proteins, through to immunoassay development and the formulation and dispensing of reagents.

biOasis Technologies Inc. is a company focused on the Health Care & Life Sciences market, and is engaged in the development and commercialization of diagnostics and therapeutic delivery systems related to neurological diseases.

Related Links:
biOasis Technologies Inc.
Fleet Bioprocessing Ltd.